IHS Chemical Week

Regions :: North America :: U.S.

Lonza Signs Manufacturing Deal with U.S. Biopharma Firm

11:49 PM MST | November 25, 2009 | Deepti Ramesh

Lonza says it has entered into an agreement with biopharmaceutical company Micromet (Bethesda, MD) for the process development and manufacture of Micromet’s blinatumomab, a BiTE antibody for the treatment of various hematologic cancers. Micromet develops novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Lonza will manufacture blinatumomab for clinical trials, under the terms of the deal. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if requested by...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa